Songjiang Ma Sells 2,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $11.05, for a total transaction of $22,100.00. Following the transaction, the president now directly owns 2,940,467 shares of the company’s stock, valued at $32,492,160.35. This represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Gyre Therapeutics Trading Up 4.5 %

NASDAQ GYRE opened at $11.14 on Friday. The business’s 50 day moving average is $12.86 and its two-hundred day moving average is $12.58. Gyre Therapeutics, Inc. has a 12-month low of $8.26 and a 12-month high of $30.40.

Institutional Trading of Gyre Therapeutics

A number of institutional investors have recently modified their holdings of GYRE. Geode Capital Management LLC raised its position in Gyre Therapeutics by 16.9% in the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock worth $3,808,000 after acquiring an additional 43,840 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Gyre Therapeutics by 392.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock worth $1,425,000 after purchasing an additional 90,557 shares during the period. State Street Corp grew its stake in shares of Gyre Therapeutics by 8.8% during the 3rd quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after purchasing an additional 8,412 shares during the period. Advantage Alpha Capital Partners LP purchased a new position in shares of Gyre Therapeutics in the 3rd quarter valued at about $334,000. Finally, WINTON GROUP Ltd acquired a new stake in shares of Gyre Therapeutics in the second quarter valued at about $220,000. 23.99% of the stock is currently owned by hedge funds and other institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.